

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form 8-K

PROVECTUS PHARMACEUTICALS INC
Form 8-K
December 02, 2003

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 19, 2003

PROVECTUS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

Nevada	0-9410	90-0031917
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(I.R.S. Employer Identification Number)
7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee		37931
(Address of Principal Executive Offices)		(Zip Code)
Registrant's telephone number, including area code:	865/769-4011	

(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events.

On December 2, 2003, Provectus Pharmaceuticals, Inc. (the "Company") announced that it has completed a short-term unsecured debt financing in the aggregate gross amount of \$500,000 (the "Offering"). On November 19, 2003, the Company issued in a private placement to "accredited investors" under the Securities Act of 1933, as amended, (i) \$500,000 in the aggregate principal amount of its 8% unsecured convertible debentures; (ii) warrants to purchase up to 500,000 shares of the Company's common stock, \$.001 par value (the "Common Stock") at an exercise price of \$1.00 per share; and (iii) warrants to purchase up to 100,000 shares of the Company's Common Stock at an exercise price of \$1.25 per share. The Company will use the proceeds of the Offering to provide short-term working capital.

The Company issued a press release which is attached hereto as Exhibit 99.1 and incorporate herein by reference.

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form 8-K

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits.

Exhibits required by Item 601 of Regulation S-B are incorporated herein by reference and are listed on the attached Exhibit Index, which begins on page X-1 of this Current Report on Form 8-K.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Provectus Pharmaceuticals, Inc.

Dated: December 2, 2003

By: /s/ H. Craig Dees

H. Craig Dees
Chief Executive Officer

Exhibit Index

Exhibit No.	Description
-----	-----
99.1	Press Release of Provectus Pharmaceuticals, Inc.